Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 18/20 | 0.92 |
| ▸ | RAF1 | P04049 | 1/20 | 0.92 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5406959 | 1.00 | BRAF (0.92) | BRAFRAF1ALOX5 | |
| Sb590885 SCHEMBL14754822 | 0.96 | BRAF (1.00) | BRAFRAF1 | |
| Sb590885 SCHEMBL150830 | 0.96 | BRAF (1.00) | BRAFRAF1 | |
| Sb590885 SCHEMBL131578 | 0.96 | BRAF (1.00) | BRAFRAF1 | |
| Sb590885 SCHEMBL12518520 | 0.92 | BRAF (0.93) | BRAFRAF1ALOX5 | |
| Sb590885 SCHEMBL15667975 | 0.92 | BRAF (0.93) | BRAFRAF1ALOX5 | |
| Sb590885 SCHEMBL29353074 | 0.92 | BRAF (0.93) | BRAFRAF1ALOX5 | |
| Sb590885 SCHEMBL15442151 | 0.92 | BRAF (0.93) | BRAFRAF1ALOX5 | |
| SCHEMBL15449798 | 0.90 | BRAF (0.82) | BRAFRAF1 | |
| SCHEMBL5402908 | 0.87 | BRAF (0.71) | BRAFRAF1ALOX5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7199137-B2 | Imidazole derivatives as Raf kinase inhibitors | SMITHKLINE BEECHAM PLC (GB) | 2007-04-03 | — | — | US | claimed |
| EP-1318992-B1 | IMIDAZOLE DERIVATIVES AS RAF KINASE INHIBITORS | SMITHKLINE BEECHAM PLC (GB) | 2005-07-27 | — | — | EP | claimed |
| US-20070135433-A1 | IMIDAZOLE DERIVATIVES AS RAF KINASE INHIBITORS | DEAN DAVID K | 2007-06-14 | — | — | US | disclosed |
| US-7199137-B2 | Imidazole derivatives as Raf kinase inhibitors | SMITHKLINE BEECHAM PLC (GB) | 2007-04-03 | — | — | US | disclosed |
| US-20050176740-A1 | Cancer treatment method comprising administering an erb-family inhibitor and a raf and/or ras inhibitor | SMITHKLINE BEECHAM CORPORATION | 2005-08-11 | — | — | US | disclosed |
| EP-1492568-A1 | CANCER TREATMENT METHOD COMPRISING ADMINISTRATION OF AN ERB-FAMILY INHIBITOR AND A RAF AND/OR RAS INHIBITOR | SmithKline Beecham Corporation (US) | 2005-01-05 | — | — | EP | disclosed |
| US-20040038964-A1 | Imidazole derivatives as raf kinase inhibitors | SMITHKLINE BEECHAM P.L.C. (GB) | 2004-02-26 | — | — | US | disclosed |
| WO-2003086467-A1 | CANCER TREATMENT METHOD COMPRISING ADMINISTERING AN ERB-FAMILY INHIBITOR AND A RAF AND/OR RAS INHIBITOR | SMITHKLINE BEECHAM CORPORATION (US) | 2003-10-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050176740-A1 | Cancer treatment method comprising administering an erb-family inhibitor and a raf and/or ras inhibitor | BRAF, KRAS, NRAS | BRAF 1/4885RAF1 5/4885ALOX5 3592/4885 |
| US-20070135433-A1 | IMIDAZOLE DERIVATIVES AS RAF KINASE INHIBITORS | BRAF, RAF1, ARAF | BRAF 1/4885RAF1 2/4885ALOX5 3691/4885 |
| US-20040038964-A1 | Imidazole derivatives as raf kinase inhibitors | BRAF, RAF1, ARAF | BRAF 1/4885RAF1 2/4885ALOX5 2812/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.